Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection : Results of a 12-month randomized, double blind, placebo-controlled study
Ninety-one Helicobacter pylori-positive patients with nonulcer dyspepsia were randomized to receive either lansoprazole, amoxicillin, and clarithromycin or lansoprazole and placebo. A validated questionnaire assessed dyspeptic symptoms at baseline and at 3, 6, and 12 months. Endoscopies and biopsies...
Gespeichert in:
| Veröffentlicht in: | Digestive diseases and sciences 2006, Vol.51 (1), p.89-98 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 98 |
|---|---|
| container_issue | 1 |
| container_start_page | 89 |
| container_title | Digestive diseases and sciences |
| container_volume | 51 |
| creator | MAZZOLENI, Luiz E SANDER, Guilherme B CARTELL, André EDELWEISS, Maria I. A UCHOA, Diego M PROLLA, Joao C OTT, Eduardo A BARROS, Sérgio G. S FRANCESCONI, Carlos F POLANCZYK, Carisi A WORTMANN, André C THEIL, Alexandro L FRITSCHER, Leandro G RIVERO, Luis F |
| description | Ninety-one Helicobacter pylori-positive patients with nonulcer dyspepsia were randomized to receive either lansoprazole, amoxicillin, and clarithromycin or lansoprazole and placebo. A validated questionnaire assessed dyspeptic symptoms at baseline and at 3, 6, and 12 months. Endoscopies and biopsies were performed at baseline and at 3 and 12 months. There was an overall trend, although not statistically significant, for a benefit of H. pylori eradication. Of the patients in the antibiotics group, 16 of 46 (35%) had symptomatic improvement, versus 9 of 43 (21%) in the control group (P = 0.164). In a secondary analysis, it was found that of the patients without endoscopic gastric erosions, 15 of 34 (44%) in the antibiotics group and 5 of 33 (15%) of controls had symptomatic improvement (P = 0.015). Helicobacter pylori eradication did not prove to be clinically beneficial, although a tendency to symptomatic benefit was detected. Further studies are necessary to confirm the implications of endoscopic gastric erosions in these patients. |
| doi_str_mv | 10.1007/s10620-006-3090-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70672229</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20796274</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-f61dc7cff4cfa9a097958f89d18e9e484083967390eb0887c6e1c1302dba6f2e3</originalsourceid><addsrcrecordid>eNqFksGKFDEQhhtxccfVB_AiQdCTrZV0TzrxJoO6CwuC6LlJJxUnSzppk25lfMZ9qE3vDCx48ZTk5_urUsVfVS8ovKMA3ftMgTOoAXjdgISaP6o2dNs1Ndty8bjaAOXlTik_r57mfAMAsqP8SXVOeUs5o2JT3e68C04rT-Iy6zhiJtESTMoUcXYxrM9L9E7HQekZE5kOPiZHXCAhhsXrIplDnnDKTq2qIlOcFn80_3Hzvih793NPpoS_lcegca3pgkV9z3wg3zAvfr7vrAhl9RhDsSUVTBzdXzRviYnL4JEM5bPlNXmlcYi1LlyK3qMheV7M4Vl1ZpXP-Px0XlQ_Pn_6vrusr79-udp9vK51GXuuLadGd9raVlslVVmK3AorpKECJbaiBdFI3jUScAAhOs2RatoAM4PilmFzUb051p1S_LVgnvvRZY3eq4BxyX0HvGOMyf-CDDrJWdcW8NU_4E1cUihD9Iy2pXUDvED0COkUc05o-ym5UaVDT6FfA9EfA9GXQPRrIPrV8_JUeBlGNA-OUwIK8PoEqFxiYMvWtcsPnKBMCtE0dxstwQc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>214302306</pqid></control><display><type>article</type><title>Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection : Results of a 12-month randomized, double blind, placebo-controlled study</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>MAZZOLENI, Luiz E ; SANDER, Guilherme B ; CARTELL, André ; EDELWEISS, Maria I. A ; UCHOA, Diego M ; PROLLA, Joao C ; OTT, Eduardo A ; BARROS, Sérgio G. S ; FRANCESCONI, Carlos F ; POLANCZYK, Carisi A ; WORTMANN, André C ; THEIL, Alexandro L ; FRITSCHER, Leandro G ; RIVERO, Luis F</creator><creatorcontrib>MAZZOLENI, Luiz E ; SANDER, Guilherme B ; CARTELL, André ; EDELWEISS, Maria I. A ; UCHOA, Diego M ; PROLLA, Joao C ; OTT, Eduardo A ; BARROS, Sérgio G. S ; FRANCESCONI, Carlos F ; POLANCZYK, Carisi A ; WORTMANN, André C ; THEIL, Alexandro L ; FRITSCHER, Leandro G ; RIVERO, Luis F</creatorcontrib><description>Ninety-one Helicobacter pylori-positive patients with nonulcer dyspepsia were randomized to receive either lansoprazole, amoxicillin, and clarithromycin or lansoprazole and placebo. A validated questionnaire assessed dyspeptic symptoms at baseline and at 3, 6, and 12 months. Endoscopies and biopsies were performed at baseline and at 3 and 12 months. There was an overall trend, although not statistically significant, for a benefit of H. pylori eradication. Of the patients in the antibiotics group, 16 of 46 (35%) had symptomatic improvement, versus 9 of 43 (21%) in the control group (P = 0.164). In a secondary analysis, it was found that of the patients without endoscopic gastric erosions, 15 of 34 (44%) in the antibiotics group and 5 of 33 (15%) of controls had symptomatic improvement (P = 0.015). Helicobacter pylori eradication did not prove to be clinically beneficial, although a tendency to symptomatic benefit was detected. Further studies are necessary to confirm the implications of endoscopic gastric erosions in these patients.</description><identifier>ISSN: 0163-2116</identifier><identifier>EISSN: 1573-2568</identifier><identifier>DOI: 10.1007/s10620-006-3090-6</identifier><identifier>PMID: 16416218</identifier><identifier>CODEN: DDSCDJ</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>2-Pyridinylmethylsulfinylbenzimidazoles ; Adolescent ; Adult ; Aged ; Amoxicillin - therapeutic use ; Anti-Infective Agents - therapeutic use ; Bacterial diseases ; Bacterial diseases of the digestive system and abdomen ; Biological and medical sciences ; Biopsy ; Brazil - epidemiology ; Clarithromycin - therapeutic use ; Double-Blind Method ; Drug Therapy, Combination ; Dyspepsia - drug therapy ; Dyspepsia - etiology ; Dyspepsia - pathology ; Endoscopy, Gastrointestinal ; Feeding. Feeding behavior ; Female ; Follow-Up Studies ; Fundamental and applied biological sciences. Psychology ; Gastric Mucosa - microbiology ; Gastric Mucosa - pathology ; Gastritis - complications ; Gastritis - drug therapy ; Gastritis - microbiology ; Gastroenterology. Liver. Pancreas. Abdomen ; Helicobacter Infections - drug therapy ; Helicobacter Infections - epidemiology ; Helicobacter Infections - microbiology ; Helicobacter pylori ; Helicobacter pylori - isolation & purification ; Human bacterial diseases ; Humans ; Infectious diseases ; Lansoprazole ; Male ; Medical sciences ; Middle Aged ; Omeprazole - analogs & derivatives ; Omeprazole - therapeutic use ; Other diseases. Semiology ; Prevalence ; Prospective Studies ; Proton Pump Inhibitors ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Treatment Outcome ; Vertebrates: anatomy and physiology, studies on body, several organs or systems</subject><ispartof>Digestive diseases and sciences, 2006, Vol.51 (1), p.89-98</ispartof><rights>2006 INIST-CNRS</rights><rights>Springer Science + Business Media, Inc. 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-f61dc7cff4cfa9a097958f89d18e9e484083967390eb0887c6e1c1302dba6f2e3</citedby><cites>FETCH-LOGICAL-c416t-f61dc7cff4cfa9a097958f89d18e9e484083967390eb0887c6e1c1302dba6f2e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,4010,27904,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18129883$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16416218$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MAZZOLENI, Luiz E</creatorcontrib><creatorcontrib>SANDER, Guilherme B</creatorcontrib><creatorcontrib>CARTELL, André</creatorcontrib><creatorcontrib>EDELWEISS, Maria I. A</creatorcontrib><creatorcontrib>UCHOA, Diego M</creatorcontrib><creatorcontrib>PROLLA, Joao C</creatorcontrib><creatorcontrib>OTT, Eduardo A</creatorcontrib><creatorcontrib>BARROS, Sérgio G. S</creatorcontrib><creatorcontrib>FRANCESCONI, Carlos F</creatorcontrib><creatorcontrib>POLANCZYK, Carisi A</creatorcontrib><creatorcontrib>WORTMANN, André C</creatorcontrib><creatorcontrib>THEIL, Alexandro L</creatorcontrib><creatorcontrib>FRITSCHER, Leandro G</creatorcontrib><creatorcontrib>RIVERO, Luis F</creatorcontrib><title>Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection : Results of a 12-month randomized, double blind, placebo-controlled study</title><title>Digestive diseases and sciences</title><addtitle>Dig Dis Sci</addtitle><description>Ninety-one Helicobacter pylori-positive patients with nonulcer dyspepsia were randomized to receive either lansoprazole, amoxicillin, and clarithromycin or lansoprazole and placebo. A validated questionnaire assessed dyspeptic symptoms at baseline and at 3, 6, and 12 months. Endoscopies and biopsies were performed at baseline and at 3 and 12 months. There was an overall trend, although not statistically significant, for a benefit of H. pylori eradication. Of the patients in the antibiotics group, 16 of 46 (35%) had symptomatic improvement, versus 9 of 43 (21%) in the control group (P = 0.164). In a secondary analysis, it was found that of the patients without endoscopic gastric erosions, 15 of 34 (44%) in the antibiotics group and 5 of 33 (15%) of controls had symptomatic improvement (P = 0.015). Helicobacter pylori eradication did not prove to be clinically beneficial, although a tendency to symptomatic benefit was detected. Further studies are necessary to confirm the implications of endoscopic gastric erosions in these patients.</description><subject>2-Pyridinylmethylsulfinylbenzimidazoles</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Amoxicillin - therapeutic use</subject><subject>Anti-Infective Agents - therapeutic use</subject><subject>Bacterial diseases</subject><subject>Bacterial diseases of the digestive system and abdomen</subject><subject>Biological and medical sciences</subject><subject>Biopsy</subject><subject>Brazil - epidemiology</subject><subject>Clarithromycin - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Dyspepsia - drug therapy</subject><subject>Dyspepsia - etiology</subject><subject>Dyspepsia - pathology</subject><subject>Endoscopy, Gastrointestinal</subject><subject>Feeding. Feeding behavior</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Gastric Mucosa - microbiology</subject><subject>Gastric Mucosa - pathology</subject><subject>Gastritis - complications</subject><subject>Gastritis - drug therapy</subject><subject>Gastritis - microbiology</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Helicobacter Infections - drug therapy</subject><subject>Helicobacter Infections - epidemiology</subject><subject>Helicobacter Infections - microbiology</subject><subject>Helicobacter pylori</subject><subject>Helicobacter pylori - isolation & purification</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Lansoprazole</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Omeprazole - analogs & derivatives</subject><subject>Omeprazole - therapeutic use</subject><subject>Other diseases. Semiology</subject><subject>Prevalence</subject><subject>Prospective Studies</subject><subject>Proton Pump Inhibitors</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Treatment Outcome</subject><subject>Vertebrates: anatomy and physiology, studies on body, several organs or systems</subject><issn>0163-2116</issn><issn>1573-2568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFksGKFDEQhhtxccfVB_AiQdCTrZV0TzrxJoO6CwuC6LlJJxUnSzppk25lfMZ9qE3vDCx48ZTk5_urUsVfVS8ovKMA3ftMgTOoAXjdgISaP6o2dNs1Ndty8bjaAOXlTik_r57mfAMAsqP8SXVOeUs5o2JT3e68C04rT-Iy6zhiJtESTMoUcXYxrM9L9E7HQekZE5kOPiZHXCAhhsXrIplDnnDKTq2qIlOcFn80_3Hzvih793NPpoS_lcegca3pgkV9z3wg3zAvfr7vrAhl9RhDsSUVTBzdXzRviYnL4JEM5bPlNXmlcYi1LlyK3qMheV7M4Vl1ZpXP-Px0XlQ_Pn_6vrusr79-udp9vK51GXuuLadGd9raVlslVVmK3AorpKECJbaiBdFI3jUScAAhOs2RatoAM4PilmFzUb051p1S_LVgnvvRZY3eq4BxyX0HvGOMyf-CDDrJWdcW8NU_4E1cUihD9Iy2pXUDvED0COkUc05o-ym5UaVDT6FfA9EfA9GXQPRrIPrV8_JUeBlGNA-OUwIK8PoEqFxiYMvWtcsPnKBMCtE0dxstwQc</recordid><startdate>2006</startdate><enddate>2006</enddate><creator>MAZZOLENI, Luiz E</creator><creator>SANDER, Guilherme B</creator><creator>CARTELL, André</creator><creator>EDELWEISS, Maria I. A</creator><creator>UCHOA, Diego M</creator><creator>PROLLA, Joao C</creator><creator>OTT, Eduardo A</creator><creator>BARROS, Sérgio G. S</creator><creator>FRANCESCONI, Carlos F</creator><creator>POLANCZYK, Carisi A</creator><creator>WORTMANN, André C</creator><creator>THEIL, Alexandro L</creator><creator>FRITSCHER, Leandro G</creator><creator>RIVERO, Luis F</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>2006</creationdate><title>Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection : Results of a 12-month randomized, double blind, placebo-controlled study</title><author>MAZZOLENI, Luiz E ; SANDER, Guilherme B ; CARTELL, André ; EDELWEISS, Maria I. A ; UCHOA, Diego M ; PROLLA, Joao C ; OTT, Eduardo A ; BARROS, Sérgio G. S ; FRANCESCONI, Carlos F ; POLANCZYK, Carisi A ; WORTMANN, André C ; THEIL, Alexandro L ; FRITSCHER, Leandro G ; RIVERO, Luis F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-f61dc7cff4cfa9a097958f89d18e9e484083967390eb0887c6e1c1302dba6f2e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>2-Pyridinylmethylsulfinylbenzimidazoles</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Amoxicillin - therapeutic use</topic><topic>Anti-Infective Agents - therapeutic use</topic><topic>Bacterial diseases</topic><topic>Bacterial diseases of the digestive system and abdomen</topic><topic>Biological and medical sciences</topic><topic>Biopsy</topic><topic>Brazil - epidemiology</topic><topic>Clarithromycin - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Dyspepsia - drug therapy</topic><topic>Dyspepsia - etiology</topic><topic>Dyspepsia - pathology</topic><topic>Endoscopy, Gastrointestinal</topic><topic>Feeding. Feeding behavior</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Gastric Mucosa - microbiology</topic><topic>Gastric Mucosa - pathology</topic><topic>Gastritis - complications</topic><topic>Gastritis - drug therapy</topic><topic>Gastritis - microbiology</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Helicobacter Infections - drug therapy</topic><topic>Helicobacter Infections - epidemiology</topic><topic>Helicobacter Infections - microbiology</topic><topic>Helicobacter pylori</topic><topic>Helicobacter pylori - isolation & purification</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Lansoprazole</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Omeprazole - analogs & derivatives</topic><topic>Omeprazole - therapeutic use</topic><topic>Other diseases. Semiology</topic><topic>Prevalence</topic><topic>Prospective Studies</topic><topic>Proton Pump Inhibitors</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Treatment Outcome</topic><topic>Vertebrates: anatomy and physiology, studies on body, several organs or systems</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MAZZOLENI, Luiz E</creatorcontrib><creatorcontrib>SANDER, Guilherme B</creatorcontrib><creatorcontrib>CARTELL, André</creatorcontrib><creatorcontrib>EDELWEISS, Maria I. A</creatorcontrib><creatorcontrib>UCHOA, Diego M</creatorcontrib><creatorcontrib>PROLLA, Joao C</creatorcontrib><creatorcontrib>OTT, Eduardo A</creatorcontrib><creatorcontrib>BARROS, Sérgio G. S</creatorcontrib><creatorcontrib>FRANCESCONI, Carlos F</creatorcontrib><creatorcontrib>POLANCZYK, Carisi A</creatorcontrib><creatorcontrib>WORTMANN, André C</creatorcontrib><creatorcontrib>THEIL, Alexandro L</creatorcontrib><creatorcontrib>FRITSCHER, Leandro G</creatorcontrib><creatorcontrib>RIVERO, Luis F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive diseases and sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MAZZOLENI, Luiz E</au><au>SANDER, Guilherme B</au><au>CARTELL, André</au><au>EDELWEISS, Maria I. A</au><au>UCHOA, Diego M</au><au>PROLLA, Joao C</au><au>OTT, Eduardo A</au><au>BARROS, Sérgio G. S</au><au>FRANCESCONI, Carlos F</au><au>POLANCZYK, Carisi A</au><au>WORTMANN, André C</au><au>THEIL, Alexandro L</au><au>FRITSCHER, Leandro G</au><au>RIVERO, Luis F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection : Results of a 12-month randomized, double blind, placebo-controlled study</atitle><jtitle>Digestive diseases and sciences</jtitle><addtitle>Dig Dis Sci</addtitle><date>2006</date><risdate>2006</risdate><volume>51</volume><issue>1</issue><spage>89</spage><epage>98</epage><pages>89-98</pages><issn>0163-2116</issn><eissn>1573-2568</eissn><coden>DDSCDJ</coden><abstract>Ninety-one Helicobacter pylori-positive patients with nonulcer dyspepsia were randomized to receive either lansoprazole, amoxicillin, and clarithromycin or lansoprazole and placebo. A validated questionnaire assessed dyspeptic symptoms at baseline and at 3, 6, and 12 months. Endoscopies and biopsies were performed at baseline and at 3 and 12 months. There was an overall trend, although not statistically significant, for a benefit of H. pylori eradication. Of the patients in the antibiotics group, 16 of 46 (35%) had symptomatic improvement, versus 9 of 43 (21%) in the control group (P = 0.164). In a secondary analysis, it was found that of the patients without endoscopic gastric erosions, 15 of 34 (44%) in the antibiotics group and 5 of 33 (15%) of controls had symptomatic improvement (P = 0.015). Helicobacter pylori eradication did not prove to be clinically beneficial, although a tendency to symptomatic benefit was detected. Further studies are necessary to confirm the implications of endoscopic gastric erosions in these patients.</abstract><cop>Heidelberg</cop><pub>Springer</pub><pmid>16416218</pmid><doi>10.1007/s10620-006-3090-6</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0163-2116 |
| ispartof | Digestive diseases and sciences, 2006, Vol.51 (1), p.89-98 |
| issn | 0163-2116 1573-2568 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70672229 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | 2-Pyridinylmethylsulfinylbenzimidazoles Adolescent Adult Aged Amoxicillin - therapeutic use Anti-Infective Agents - therapeutic use Bacterial diseases Bacterial diseases of the digestive system and abdomen Biological and medical sciences Biopsy Brazil - epidemiology Clarithromycin - therapeutic use Double-Blind Method Drug Therapy, Combination Dyspepsia - drug therapy Dyspepsia - etiology Dyspepsia - pathology Endoscopy, Gastrointestinal Feeding. Feeding behavior Female Follow-Up Studies Fundamental and applied biological sciences. Psychology Gastric Mucosa - microbiology Gastric Mucosa - pathology Gastritis - complications Gastritis - drug therapy Gastritis - microbiology Gastroenterology. Liver. Pancreas. Abdomen Helicobacter Infections - drug therapy Helicobacter Infections - epidemiology Helicobacter Infections - microbiology Helicobacter pylori Helicobacter pylori - isolation & purification Human bacterial diseases Humans Infectious diseases Lansoprazole Male Medical sciences Middle Aged Omeprazole - analogs & derivatives Omeprazole - therapeutic use Other diseases. Semiology Prevalence Prospective Studies Proton Pump Inhibitors Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Treatment Outcome Vertebrates: anatomy and physiology, studies on body, several organs or systems |
| title | Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection : Results of a 12-month randomized, double blind, placebo-controlled study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T11%3A48%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20outcomes%20of%20eradication%20of%20Helicobacter%20pylori%20in%20nonulcer%20dyspepsia%20in%20a%20population%20with%20a%20high%20prevalence%20of%20infection%20:%20Results%20of%20a%2012-month%20randomized,%20double%20blind,%20placebo-controlled%20study&rft.jtitle=Digestive%20diseases%20and%20sciences&rft.au=MAZZOLENI,%20Luiz%20E&rft.date=2006&rft.volume=51&rft.issue=1&rft.spage=89&rft.epage=98&rft.pages=89-98&rft.issn=0163-2116&rft.eissn=1573-2568&rft.coden=DDSCDJ&rft_id=info:doi/10.1007/s10620-006-3090-6&rft_dat=%3Cproquest_cross%3E20796274%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=214302306&rft_id=info:pmid/16416218&rfr_iscdi=true |